Catch­ing up with Bris­tol My­ers and Mer­ck, As­traZeneca de­clares neoad­ju­vant win for PD-L1/chemo com­bo

When As­traZeneca start­ed the Phase III AEGEAN tri­al for Imfinzi in 2018, it was, along­side sev­er­al Big Phar­ma brethren, hop­ing to push the use of PD-(L)1 ther­a­pies in­to ear­li­er lines of treat­ment. Three and a half years lat­er, the British drug­mak­er has nabbed promis­ing da­ta in a type of lung can­cer.

Topline re­sults from an in­ter­im analy­sis showed that adding Imfinzi to chemother­a­py be­fore surgery spurred a “sta­tis­ti­cal­ly sig­nif­i­cant and mean­ing­ful” im­prove­ment in patho­log­ic com­plete re­sponse for pa­tients with re­sectable non-small cell lung can­cer com­pared to chemother­a­py alone.

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER